Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

TORONTO, December 28, 2022—(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or “Society“) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotechnology company focused on developing the next generation of medicines to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the healing power of psychedelic molecules, is pleased to announce that successfully completed the …

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease Read More »